Low-dose capecitabine after throat cancer treatment
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This study tests whether low-dose capecitabine given after standard treatment can lower the chance that locoregional (nearby) throat cancer returns. It is designed for adults with advanced hypopharyngeal (throat) cancer who have finished curative chemoradiation or surgery and follow-up therapy and show no active cancer on exam.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 65 years old.
- Your diagnosis is hypopharyngeal (throat) cancer, stage IV by the study’s staging rules, and you completed the standard curative treatment (either chemoradiation or surgery plus follow-up therapy).
- After your definitive chemoradiotherapy, doctors do not see any remaining nearby tumor or distant spread.
- You are starting the study within 8 weeks after your last radiation treatment.
- Your body can safely tolerate the study: blood counts, liver tests, and kidney function are within allowed ranges, and your activity level is ECOG 0–1 (able to carry out daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a low-dose, frequent regimen of the chemotherapy drug capecitabine (taken as a pill) to see if it can help prevent stage III stomach cancer from coming back after surgery. It's for people who have had their stomach cancer completely removed with a specific type of lymph node dissection.
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This trial tests whether taking capecitabine pills on a steady, low schedule after standard treatment can help keep locally advanced head and neck squamous cell cancer from coming back or spreading. You may be eligible if your cancer is stage III–IV and you have finished certain radiation/chemo treatments on time, without current spread.
This trial tests whether giving the chemotherapy drug capecitabine (Xeloda) before surgery helps shrink head and neck cancers that are not linked to HPV. It is for people with early to moderately advanced disease who have not yet had any treatment.
This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.
Hear when a new to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.